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Background: Because of the infrequence of salivary gland tumours and their complex histopathological diagnosis
it is still difficult to exactly predict their clinical course by means of recurrence, malignant progression and
metastasis. In order to define new proliferation associated genes, purpose of this study was to investigate the
expression of human α-defensins (DEFA) 1/3 and 4 in different tumour entities of the salivary glands with respect to
malignancy.
Methods: Tissue of salivary glands (n=10), pleomorphic adenomas (n=10), cystadenolymphomas (n=10),
adenocarcinomas (n=10), adenoidcystic carcinomas (n=10), and mucoepidermoid carcinomas (n=10) was obtained
during routine surgical procedures. RNA was extracted according to standard protocols. Transcript levels of DEFA
1/3 and 4 were analyzed by quantitative realtime PCR and compared with healthy salivary gland tissue. Additionally,
the proteins encoded by DEFA 1/3 and DEFA 4 were visualized in paraffin-embedded tissue sections by
immunohistochemical staining.
Results: Human α-defensins are traceable in healthy as well as in pathological altered salivary gland tissue. In
comparison with healthy tissue, the gene expression of DEFA 1/3 and 4 was significantly (p<0.05) increased in all
tumours – except for a significant decrease of DEFA 4 gene expression in pleomorphic adenomas and a similar
transcript level for DEFA 1/3 compared to healthy salivary glands.
Conclusions: A decreased gene expression of DEFA 1/3 and 4 might protect pleomorphic adenomas from
malignant transformation into adenocarcinomas. A similar expression pattern of DEFA-1/3 and -4 in
cystadenolymphomas and inflamed salivary glands underlines a potential importance of immunological reactions
during the formation of Warthin’s tumour.
Keywords: DEFA 1/3, DEFA 4, Salivary gland, Tumour, DefensinsBackground
Salivary gland tumours are a rare tumour entity: they
have a prevalence of 2-3% among the head and neck
cancers and a proportion of less than 0.5 percent of all
malignant tumours. Their majority is benign, but malig-
nant salivary gland tumours occur in 15 to 32 percent of
the patients. In the most cases they derive from the six
major salivary glands (parotid, submandibular, and* Correspondence: m.wenghoefer@gmx.de
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reproduction in any medium, provided the orsublingual gland), most commonly from the parotid
gland in up to 80 percent of all cases [1].
The exact histopathological diagnosis is complicated
by a wide variety of different morphologic features. Sal-
ivary gland tumours might be subdivided by their main
histopathological features into tumours with a) myoe-
pithelial components, b) basaloid components, c) epithe-
lial components, d) lymphatic components and e)
pleomorphic adenomas [2].
As salivary gland tumours are not very frequent and
their histopathological diagnosis is complex, at present
time it is difficult to exactly predict their clinical courseLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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metastasis. Therefore molecular biology has moved
into the focus of tumour research. Like in other epi-
thelial tumours a number of proliferation associated
antigens as Ki-67, proto-oncogenes as bcl-2, tumour
suppressor genes as p53 or p21 and the overexpression
of growth-factor binding receptors as HER-2 have been
identified as important factors in the malignant pro-
gression of these tumors [3], but disappointingly only
a few candidate genes and their transcripts have been
clearly associated with the malignant transformation
and progression of benign salivary gland tissue into a
malignant tumour. As pleomorphic adenomas have the
tendency in up to 4% of the cases to transform into an
adenocarcinoma, they are ideal subjects to investigate
and characterise altered genes in the molecular sequence
adenoma to carcinoma. Interesting new candidate genes
which might help to a better understanding of salivary
gland tumours are human defensins [4-6].
Defensins
Antimicrobial peptides (AMPs) were first described in
the coherency of host defence, but feature besides their
antimicrobial activity a wide variety of functions in nu-
merous cellular processes. One subfamily of mammalian
AMPs are defensins, which are important components
of the innate immune system. Defensins are positively
charged peptides with molecular weights ranging from
3.5 to 6.5 kDa. They share a framework of six
disulphide-linked cysteine (cys) residues, thus forming a
characteristic β-sheet structure under physiological con-
ditions. A number of positively charged amino acids
cause their typical cationic features and is, in combin-
ation with their physical structure, responsible for their
ability to disintegrate membranes of gram-positive and
gram-negative bacteria as well as yeasts and certain
viruses. Defensins have been detected in different tissues
as the epithelia of the oral cavity, the gastrointestinal
and respiratory tract, the urinary tract and the vagina as
well as in the salivary glands [7-11].
By their physical structure human defensins could be
divided into two subgroups: α- and β-defensins, which
both consist of a triple-stranded β-sheet structure, but
mainly differ in the pairing of their cystine-disulphide
bridges. Cysteine residues in α-defensins are linked be-
tween 1-6/2-4/3-5, whereas β-defensins share a 1-5/2-4/
3-6 cys-cys pattern. By this characteristic pairing of di-
sulphide bridges, four α-defensins (DEFA) were
described, which have been isolated from the granules of
polymorphonuclear neutrophil leukocytes. Because of
their distribution in the granules of the leucocytes, they
were named human neutrophil peptides 1-4 (HNP1-4).
Additionally two α-defensins, DEFA 5 and 6 were iso-
lated from intestinal Paneth cells. The genes encodingfor the DEFAs are located on chromosome 8, remarkably
DEFA 1 differs from DEFA 3 only by one amino acid
[7,8,10-13].
In recent studies, human beta-defensins (hBDs) were
investigated in head and neck cancers - and there seems
to be a correlation between chronic inflammation and
cancers of the oral cavity, like tongue carcinomas [14,15].
This observation is consistent with prior studies con-
cerning the involvement of hBD-1 in the carcinogenesis
of epithelial tumours of the urogenital tract: Refering to
healthy epithelium showing an intact hBD-1 gene ex-
pression, there was a cancer-specific loss of hBD-1 gene
expression in 90% of renal clear cell carcinomas and
82% of malignant prostate cancers [16,17]. Recent studies
transferred this observation towards oral squamous cell
carcinomas (OSCC) in which the hBD-1 gene expression
is significantly (50-fold) reduced in comparison with
healthy gingiva [18]. As human defensins are involved in
chronic periodontal inflammation as well as carcinogen-
esis of oral tumours, it is an interesting new hypothesis
that they might act as key-molecules in the inflammation-
tumour-sequence [4-6,17,19-22]. The gene DEFB1 encod-
ing for hBD-1 has been identified as a major periodontitis-
associated gene [23] with functions in local host defence
but also seems to be an important factor in proliferation
control of oral cancers [4-6,17,19-21]. In vitro hBD-1
inhibits the proliferation of oral squamous cell carcinoma
cells [16-19], whereas hBD-2 and -3 promote their prolif-
eration [19,20]. This observation could also be made in
osteosarcoma cell lines, where hBD-2 and -3 enhance pro-
liferation [24]. Furthermore hBD-1, -2 and -3 cross-
regulate their own gene expression in OSCCs in vitro
[19,20].
So we gained some insight recently in the role which
human β-defensins might play in the carcinogenesis of
head and neck cancers – maybe they are the link be-
tween chronic inflammation and epithelial tumour initi-
ation. Because of the structural and functional
similarities between α- and β-defensins, α-defensins




In this study, tissue of inflamed salivary glands (n=10),
pleomorphic adenomas (n=10), cystadenolymphomas
(n=10), adenocarcinomas (n=10), adenoidcystic carcin-
omas (n=10), and mucoepidermoid carcinomas (n=10)
was investigated and compared with healthy salivary
gland tissue as reference. The average age at diagnosis
was 53.8 years. The healthy salivary gland tissue was col-
lected from patients with head and neck tumours during
the surgical procedure of neck dissection; those patients
were neither irradiated nor received chemotherapy.
Winter et al. BMC Cancer 2012, 12:465 Page 3 of 8
http://www.biomedcentral.com/1471-2407/12/465Procedures involving the human tissue sampling collec-
tion followed a protocol approved by the ethical board
of the University of Bonn. All patients had been
informed about the study and had signed a letter of
informed consent.
Immunohistochemistry
After formalin fixation, the tissue samples were embed-
ded in paraffin and cut with a standard microtome
(Reichert-Jung, Heidelberg, Germany) into 2μm sections.
Tissues for light microscopic evaluation were stained
with Hematoxylin and Eosin (HE) and the diagnosis was
confirmed by a pathologist.
Formalinfixed, paraffin-embedded tissue sections
were used for immunohistochemical staining. After
deparaffinization and rehydration, the slides were
washed in Tris-buffered saline (TBS) containing 1%
bovine serum albumin (BSA). Endogenous peroxidase
activity was quenched by incubating the slides in a
methanolic solution of 0.3% hydrogen peroxide. Tissue
samples were blocked for unspecific binding with 1%
BSA in TBS for 1 hour at room temperature. Incuba-
tion with primary antibodies rabbit anti-DEFA 1/3 and
-DEFA 4 (Santa Cruz, Heidelberg, Germany) diluted
1:200 in 1% TBS-buffered BSA was performed over-
night at 4°C.
The slides were then washed in TBS buffer, the HRP-
conjugated secondary antibody, goat anti-rabbit (Dia-
nova, Hamburg, Germany), was added and the slides
were incubated at room temperature for 45 minutes.
Afterwards, the slides were washed in TBS buffer and
incubated with diaminobenzidine (DAB) as substrate
and counterstained with hematoxylin (Merck Eurolab,
Dietikon, Switzerland). Negative controls without pri-
mary antibody were included in each experiment to ver-
ify antibody specificity. The immuno-staining for DEFA
1/3 and DEFA 4 was analyzed using a Zeiss Axio-Imager
A.1 microscope (Zeiss, Oberkochen, Germany).
RNA extraction and first-strand cDNA synthesis
RNA was prepared only from isolated tumour sections
using the “RNeasy Protect Mini Kit” (Qiagen, Hilden,
Germany). Circumjacent non-tumourigenic tissues were
cut-off. The preparation of tumour sections was micro-
scopically verified. First-strand cDNA synthesis was
performed using "iScript™ Select cDNA Synthesis Kit"
(Bio-Rad, Munich, Germany) with oligo(dT) primers
according to the manufacturer’s protocol.
Quantitative realtime-PCR
Differential gene expression was analyzed by realtime-
PCR with the iCyclerW Thermal Cycler (Bio-Rad, Mun-
ich, Germany). SYBRW Green served as fluorophor for
online-monitoring of generated PCR-products. Allprimers were synthesized and specified by Metabion
(Metabion, Martinsried, Germany. Primer sequences are
presented in Table 1. Realtime-PCR was performed as
previously described [4,6,19,21,22,24]. An appropriate
amount of cDNA was added to a mastermix containing
primers and iQ™ SYBRW Green Supermix (Bio-Rad,
Munich, Germany). Cloned PCR-products derived from
the specific primers served as positive controls for the
PCR, while water was used as negative control. Every set
of experiment was carried out with cDNA of the
same sample to exactly compare the expression of
the different genes of interest. Glyceraldehydephosphate-
dehydrogenase (GAPDH) served as reference to normalize
the crossing point (CP).
Relative differential gene expression was calculated
using the method described by Pfaffl [25]. PCR-
efficiencies were determined with dilution series. Effi-
ciency (E) is defined with E = 10-1/slope [25]. Primer effi-
ciencies and corresponding annealing temperatures are
depicted in Table 1.Statistical analysis
In case of multiple comparisons of the investigated groups
one-way ANOVA with Dunnett´s post-test was per-
formed. All statistical analyses were performed by Graph-
Pad Prism version 5.00 for Windows, GraphPad Software
(San Diego, USA). Significant differences (p<0.05) com-
pared to control are marked with asterisks (*).Results
Human α-defensins are traceable in healthy as well as
pathological altered salivary gland tissue
In comparison with healthy tissue (set 1 as baseline), the
gene expression of DEFA-1/3 and -4 was significantly
(p<0.05) increased in all tumours. The increase for
DEFA 1/3 was in pleomorphic adenomas: 2.64-fold, in
cystadenolymphomas: 146.9-fold, in adenocarcinomas as
well as in adenoidcystic carcinomas: 48.47-fold and in
mucoepidermoid carcinomas: 27.84-fold.
The increase of DEFA 4 was in cystadenolymphomas:
48.2-fold, in adenocarcinomas: 13.9-fold, adenoidcystic
carcinomas: 14.5-fold and in mucoepidermoid carcin-
omas: 4.6-fold.
The increase of DEFA 1/3 and DEFA 4 in inflamed sal-
ivary gland tissue (146.9 and 30.3-fold respectively) was
comparable with cystadenolymphomas (146.9 and 48.2-
fold respectively).
Only in pleomorphic adenomas a 3.4-fold decrease in
DEFA 4 gene expression was evident.
The results for the relative gene expressions of DEFA
1/3 and DEFA 4 are depicted in Table 2, the results for
the comparison of all entities with healthy salivary gland
tissue are shown in Table 3 and visualized in Figure 1.
Table 1 Primer sequences with corresponding annealing temperatures, efficiencies, and product length in basepairs
(bp) used for realtime PCR
Gene Primer sequences (sense/antisense) Efficiency Annealing temperature (°C) Product length (bp)
GAPDH 5´-TGGTATCGTGGAAGGACTCA-3´ 1.93 67 132
5´-CCAGTAGAGGCAGGGATGAT-3´
DEFA1/3 5´-ATGAGGACCCTCGCCATCCTTGCT-3´ 2.17 69 285
5´-TCAGCAGCAGAATGCCCAGCGTCTTCCC-3´
DEFA4 5´-GTCTGCTCTTGCAGATTAGTATTCTG-3´ 1.98 69 105
5´-TTAATCGACACGCGTGCAGCAGTAT-3´
PCR efficiencies for every set of primers were determined with dilution series of primer specific cloned PCR-products at the corresponding annealing temperature.
Efficiency stands for the performance to amplify a cDNA template. Efficiency values of 2.0 means an amplification of 100%.
Winter et al. BMC Cancer 2012, 12:465 Page 4 of 8
http://www.biomedcentral.com/1471-2407/12/465Figure 2 shows the immunostaining for DEFA 1/3,
Figure 3 the immunostaining for DEFA 4 in pleo-
morphic adenoma tissue.
Figure 4 shows the immunostaining for DEFA 1/3,
Figure 5 the immunostaining for DEFA 4 in cystadeno-
lymphoma tissue. Primary magnification of all images
was: A=5-fold, B=10-fold, C=20-fold and D=40-fold.
Discussion
In the present study the gene expression of DEFA 1/3
ad DEFA 4 was analyzed in healthy salivary gland tis-
sue in comparison with different benign and malignant
salivary gland tumours and inflamed salivary gland tis-
sue. Additionally the peptides were visualized by
immunostaining.
Both α-defensins were detectable in healthy tissue,
inflamed tissue as well as tumour tissue. In comparison
with healthy salivary gland tissue, which was taken as
baseline, the gene expression of DEFA 1/3 and DEFA 4
was altered in all investigated tissues – but most inter-
esting were the findings in cystadenolymphomas and
pleomorphic adenomas (Tables 2 and 3):
Cystadenolymphomas, although first mentioned by
Hildebrad in 1885 [26] and more precisely described by
the German pathologist Albrecht in 1910 [27] are named
“Warthin tumor” after the American pathologist AldredTable 2 Relative gene expression (mean values with
standard deviations) of DEFA 1/3 and DEFA 4 compared
to GAPDH in healthy salivary glands, pleomorphic
adenomas, cystadenolymphomas, adenocarcinomas,
adenoidcystic carcinomas, and mucoepidermoid
carcinomas (n=10 each)
Entity DEFA 1/3 DEFA 4
Healthy salivary glands 0.0237 (0.0025) 0.00056 (0.0001)
Pleomorphic adenomas 0.0625 (0.023) 0.00016 (0.00003)
Cystadenolymphomas 3.4822 (1.69) 0.027 (0.0057)
Adenocarcinomas 1.1487 (0.62) 0.0078 (0.001)
Adenoidcystic carcinomas 1.1487 (0.51) 0.0081 (0.001)
Mucoepidermoid carcinomas 0.6597 (0.32) 0.00258 (0.0003)Warthin who published 34 years later the first two cases
of this entity in American literature [28]. Cystadenolym-
phomas are composed of a bilayered oncocytic and basa-
loid epithelium, forming cystic structures, papillae and
glands that are accompanied by a dense lymphoid
stroma [29-31]. Their origin is still a kind of cryptic
today: some authors think that they might develop of
heterotopic epithelial tissue enclosed in the lymph nodes
within the parotid gland whereas others believe that they
are adenomas with a lymphocytic infiltration [29-31].
But Interestingly recent studies have shown, that the
above mentioned epithelial component is polyclonal,
which means that it does not exhibit the clonal allelic
losses which are typical for a true neoplasm [32]. This
finding is supported by the present and further studies
of our group concerning the gene expression and distri-
bution of AMPs in different lesions of the salivary
glands.
Among the benign salivary gland tumours, pleo-
morphic adenomas are by far the most frequent aden-
oma of the parotid gland, whereas oxyphil adenomas
and other monomorphic adenoma seem to be seldom
[33]. As pleomorphic adenomas show very distinct mo-
lecular features concerning the β-defensins which differ
from other benign salivary gland tumours, it seems un-
likely, that cystadenolymphomas are adenomas with aTable 3 Differential gene expression analysis of DEFA 1/3
and DEFA 4 in pleomorphic adenomas,
cystadenolymphomas, adenocarcinomas, adenoidcystic
carcinomas, and mucoepidermoid carcinomas compared
to healthy salivary gland tissue (set as baseline = 1) –
significant differences (p<0.05) are marked with asterisks
(*)
Entity DEFA 1/3 DEFA 4
Pleomorphic adenomas 2.64* 0.29*
Cystadenolymphomas 146.9* 48.2*
Adenocarcinomas 48.47* 13.9*
Adenoidcystic carcinomas 48.47* 14.5*















Figure 1 Differential gene expression of DEFA 1/3 and DEFA 4 in different salivary gland tumors in comparison with healthy salivary
gland tissue as baseline (= 1).
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hBD-1 gene product and a decrease of hBD-1 gene ex-
pression underlines their potency for a malignant trans-
formation into adenocarcinomas [4,5]. In vitro deficiency
of insulin-like growth factor-1 (IGF-1) and a low basic
hBD-2 and hBD-3 gene expression could be protective
against a malignant transformation [6].
Because of this recent evidence that β-defensin might
play an important role in the formation and malignant
progression of salivary gland tumours, because of theirFigure 2 DEFA1/3 immunostaining in pleomorphic adenoma tissue. P
tissue section on the left in A and B (designated with "PA") shows the pleo
(designated as "HT") shows healthy tissue isolated from the biopsy. C represtructural and functional similarities and their gene loci
on chromosome 8, the present study focused on the α-
defensins. The increase of DEFA 1/3 gene expression
was in pleomorphic adenomas only slight, but in cysta-
denolymphomas very explicit. The increase of DEFA 4
was in cystadenolymphomas 48.2-fold, but in pleo-
morphic adenomas there was a 3.4-fold decrease in
DEFA 4 gene expression. This inversely alteration of
DEFA 4 gene expression and the abundantly clear differ-
ence in DEFA 1/3 gene expression additionallyrimary magnification 5-fold (A), 10-fold (B), and 40-fold (C, D). The
morphic adenoma status, the section on the right of A and B
sents the pleomorphic adenoma, D the healthy section.
Figure 3 DEFA4 immunostaining in pleomorphic adenoma tissue. Primary magnification 5-fold (A), 10-fold (B), and 40-fold (C, D). The tissue
section on the left in A and B (designated with "PA") shows the pleomorphic adenoma status, the section on the right of A and B (designated as
"HT") shows healthy tissue isolated from the biopsy. C represents the pleomorphic adenoma, D the healthy section.
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adenomas with a lymphocytic infiltration. The compar-
able increase of DEFA 1/3 and DEFA 4 in inflamed saliv-
ary gland tissue (146.9 and 30.3-fold respectively) and
cystadenolymphomas (146.9 and 48.2-fold respectively)
might suggest an inflammatory aetiology and supports
the theory, that cystadenolymphomas due to theirFigure 4 Immunostaining of DEFA1/3 in cystadenolymphoma. Primarypolyclonal epithelial component are not a true neoplasm
[32].
Pleomorphic adenomas, presenting as benign mixed
tumours, are the most common neoplasms of the major
salivary glands. Although benign, it is not uncommon
for pleomorphic adenomas to recur, and a subset of
them might undergo a malignant transformation [33]. Inmagnification 5-fold (A), 10-fold (B), 20-fold (C), and 40-fold (D).
Figure 5 Immunostaining of DEFA4 in cystadenolymphoma. Primary magnification 5-fold (A), 10-fold (B), 20-fold (C) and 40-fold (D).
Winter et al. BMC Cancer 2012, 12:465 Page 7 of 8
http://www.biomedcentral.com/1471-2407/12/465prior studies the authors demonstrated, that pleo-
morphic adenomas differ from other salivary gland
tumour in their β-defensin gene expression and the cel-
lular distribution of the hBD-1 gene product [4-6]. The
down-regulation of hBD-1 gene expression is an event
which could be observed in many tumour entities
[16-21] and which is common in head and neck cancers
also [4-6,16-21]. Additionally an up-regulation of hBD-3
was observed in oral squamous cell carcinomas (OSCC)
[19,20]. This observation led to the hypothesis that in
OSCCs hBD-1 works as a tumour-suppressor, whereas
hBD-3 is a proto-oncogene – which could be verified by
in vitro experiments [34]. In the present study pleo-
morphic adenomas clearly differ from other salivary
gland tumours by their α-defensin gene expression as
well: In comparison with healthy salivary gland tissue
the increase of DEFA 1/3 gene expression was clearly in
adenocarcinomas, adenoidcystic carcinomas and mucoe-
pidermoid carcinomas, but only slight in pleomorphic
adenomas. The gene expression of DEFA 4 was elevated
in all lesions but only in pleomorphic adenomas there
was as 3.4-fold decrease. This distribution of DEFA 4
gene expression is evocative of hBD-1 gene expression
in pleomorphic adenomas and other head and neck
cancers. It seems to be likely, that α-defensins as well
as β-defensins are involved in tumour formation and
progression of salivary gland tumours - but the inter-
pretation of α-defensin gene expression in different
head and neck lesions remains difficult and particularly
inconsistent. For example in oral leukoplakia DEFA 4
is highly up-regulated (179.2-fold) whereas DEFA 1/3does not differ much from healthy gingiva [21]. In irri-
tation fibromas of the oral cavity it is vice versa: DEFA
1/3 is up-regulated (14-fold) and DEFA 4 is compar-
able to gingiva [22]. For this reason our group at the
moment carefully investigates the influence of α-defen-
sins in different head and neck tumours in vitro. To
have this knowledge will help us to a better under-
standing of the molecular mechanisms which make a
benign tumour malignant and could therefore enable
us in the future to early diagnose and treat these
tumours.
Conclusions
It seems to be likely, that α-defensins as well as
β-defensins are involved in tumour formation and pro-
gression of salivary gland tumours. Nevertheless the in-
terpretation of α-defensin gene expression in different
head and neck lesions remains difficult. Results from this
study allow us to hypothesize that a decreased gene ex-
pression of DEFA 1/3 and 4 might protect pleomorphic
adenomas from malignant transformation into adenocar-
cinomas. A similar expression pattern of DEFA-1/3 and
-4 in cystadenolymphomas and inflamed salivary glands
underlines a potential importance of immunological
reactions during the formation of Warthin’s tumour.
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